• DA - dansk
  • EN - English
Parliamentary question - E-000921/2018(ASW)Parliamentary question
E-000921/2018(ASW)
European Parliament

Answer given by Mr Andriukaitis on behalf of the Commission

25.4.2018

Written question

The European Centre for Disease Prevention and Control has published a risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species[1].

It concludes that resistance to triazole antifungals in human Aspergillus diseases appears to have been increasing in several European countries. However, the link between the environmental use of azole fungicides and the development of triazole resistance in Aspergillus species is not yet proven.

The Commission has already invested in research on antifungal resistance and continues to do so. Successful examples are the 7th Framework Programme for Research and Technological Development (FP7) project NOFUN[2] which developed a completely new class of antifungals (patent filed) and FP7 project SYBARIS[3] which examined antifungal resistance and identified several novel molecules with potential antifungal action.

The ongoing project FUNGITECT[4] develops diagnostic tests for better-targeted treatment which may decrease the over use of antifungals that leads to fungal resistance.

The Commission adopted the ‘European one health action plan against antimicrobial resistance (AMR)’ in June 2017[5]. This sets out a comprehensive framework of actions to address AMR, including multidrug resistance in fungi. The action plan has three main pillars: to make the EU a best practice region; to boost research development and innovation; and to shape the global agenda.

Last updated: 25 April 2018
Legal notice - Privacy policy